Fesoterodine for the treatment of overactive bladder -: A cost-effectiveness case study of Sweden

被引：0
|
作者：
Prutz, C. [1 ]
Snedecor, S. [4 ]
Botteman, M. [4 ]
Trocio, J. [2 ]
Weinstein, D. [3 ]
机构：
[1] Pfizer AB, Stockholm, Sweden
[2] Pfizer Inc, New York, NY USA
[3] Pfizer France, Paris, France
[4] Pharmerit N Amer, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70951-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A302 / A302
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF FESOTERODINE AND TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER WITH URGE URINARY INCONTINENCE IN SPAIN AND FINLAND
    Angulo, J.
    Rejas, J.
    Linden, K.
    Kvasz, M. G.
    Snedecor, S. J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A633 - A633
  • [2] COST-EFFECTIVENESS OF PHARMACOLOGIC TREATMENT OF OVERACTIVE BLADDER
    Malone, D. C.
    Armstrong, E. P.
    Bui, C.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A155 - A155
  • [3] Fesoterodine for the treatment of overactive bladder
    Belavic, Jennifer M.
    [J]. NURSE PRACTITIONER, 2009, 34 (08): : 14 - 15
  • [4] Fesoterodine for the Treatment of Overactive Bladder
    Tzefos, Maria
    Dolder, Christian
    Olin, Jacqueline L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2009, 43 (12) : 1992 - 2000
  • [5] Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States
    Chen, Jing Voon
    Klein, Timothy M.
    Nesheim, Jeffrey
    Mudd, Paul N., Jr.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1092 - 1100
  • [6] Cost Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland
    Angulo, Javier C.
    Valpas, Antti
    Rejas, Javier
    Linden, Kari
    Kvasz, Marion
    Snedecor, Sonya J.
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (05) : 297 - 307
  • [7] Cost Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland
    Javier C. Angulo
    Antti Valpas
    Javier Rejas
    Kari Linden
    Marion Kvasz
    Sonya J. Snedecor
    [J]. Clinical Drug Investigation, 2014, 34 : 297 - 307
  • [8] Cost-effectiveness of novel therapies for overactive bladder
    Mayr, Craig A.
    Shepherd, Jonathan P.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) : 527 - 535
  • [9] Role of fesoterodine in the treatment of overactive bladder
    Mansfield, Kylie J.
    [J]. RESEARCH AND REPORTS IN UROLOGY, 2010, 2 : 1 - 9
  • [10] COST-EFFECTIVENESS OF MIRABEGRON VERSUS ANTIMUSCARINICS FOR THE TREATMENT OF OVERACTIVE BLADDER IN ARGENTINA
    Ramos, B.
    Sanchez Trujillo, L. A.
    Walker, D.
    Anaya, P.
    [J]. VALUE IN HEALTH, 2020, 23 : S378 - S378
12345